Bone Morphogenetic Protein Delivery Systems

Study Design. A review was conducted. Objectives. To review the rationale for the use of carrier systems to deliver bone morphogenetic proteins to sites of orthopedic repair, and to discuss commonly used carriers. Summary of Background Data. Carriers for bone morphogenetic protein in spine fusion are used to increase the retention of these osteogenic factors at the treatment site, and to serve as an osteoconductive matrix for bone forming cells while maintaining a space or volume in which bone formation can occur. Methods. The literature is reviewed and discussed. Results. Although bone morphogenetic proteins can induce bone formation when delivered in formulation buffer in small animal models, carriers often are used in larger animal models and human clinical trials to maintain the concentration of osteogenic factors at the treatment site for a sufficient period to allow bone-forming cells to migrate to the area of injury and to proliferate and differentiate. For spine fusion, carriers also are required to serve as an osteoconductive matrix for bone-forming cells while maintaining a space or volume in which bone formation can occur. Four major categories of carrier materials are used for osteogenic factor delivery: inorganic materials, synthetic polymers, natural polymers, and composites of the first three materials. In addition, allograft bone has been used to deliver osteogenic factors to the site of orthopedic repairs. The efficacy of osteogenic carrier combinations often is site specific and species specific. The requirement for supraphysiologic concentrations of osteogenic factors may be related to the ability of the delivery system to increase the retention time at the treatment site and overcome tight regulation of these factors by their inhibitors. Dose escalation in large animal models also may be related to a decrease in the number of responding cells and a slower rate of bone formation. New delivery systems being evaluated include depot delivery systems, viral vector systems, conjugated osteogenic factor delivery systems, and oral small molecule targets. Conclusions. Delivery systems play an important role in the use of osteogenic factors to augment spine fusions and other orthopedic repairs.

[1]  S. Boden,et al.  Demineralized bone matrix, bone morphogenetic proteins, and animal models of spine fusion: an overview , 2001, European Spine Journal.

[2]  A. Simpson,et al.  Osteoprogenitor cells of mature human skeletal muscle tissue: an in vitro study. , 2001, Bone.

[3]  J. Poser,et al.  Spinal fusion with recombinant human growth and differentiation factor‐5 combined with a mineralized collagen matrix , 2001, The Anatomical record.

[4]  J. Wozney,et al.  Delivering on the promise of bone morphogenetic proteins. , 2001, Trends in biotechnology.

[5]  Freddie H. Fu,et al.  Effect of Bone Morphogenetic Protein-2-Expressing Muscle-Derived Cells on Healing of Critical-Sized Bone Defects in Mice , 2001, The Journal of bone and joint surgery. American volume.

[6]  P. Robbins,et al.  The effect of bone morphogenetic protein-2 expression on the early fate of skeletal muscle-derived cells. , 2001, Bone.

[7]  S. Boden Evaluation of carriers of bone morphogenetic protein for spinal fusion. , 2001, Spine.

[8]  H. Seeherman The influence of delivery vehicles and their properties on the repair of segmental defects and fractures with osteogenic factors. , 2001, The Journal of bone and joint surgery. American volume.

[9]  J. M. Jenner,et al.  Biomechanical and histological aspects of fracture healing, stimulated with osteogenic protein-1. , 2001, Biomaterials.

[10]  A. Reddi Bone Morphogenetic Proteins: From Basic Science to Clinical Applications , 2001, The Journal of bone and joint surgery. American volume.

[11]  P. Aspenberg,et al.  The Bone Morphogenetic Proteins Antagonist Noggin Inhibits Membranous Ossification , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  Manohar M. Panjabi,et al.  Evaluation of OP-1 as a Graft Substitute for Intertransverse Process Lumbar Fusion , 2001, Spine.

[13]  H. Reddi Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN , 2000, Arthritis research.

[14]  J. Lee,et al.  Osteoprogenitor cells within skeletal muscle , 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[15]  C. Kirker-Head,et al.  Potential applications and delivery strategies for bone morphogenetic proteins. , 2000, Advanced drug delivery reviews.

[16]  R. Rutherford,et al.  Gene therapy for bone formation: In vitro and in vivo osteogenic activity of an adenovirus expressing BMP7 , 2000, Journal of cellular biochemistry.

[17]  J O Hollinger,et al.  Options for tissue engineering to address challenges of the aging skeleton. , 2000, Tissue engineering.

[18]  A. Reddi,et al.  Morphogenesis and tissue engineering of bone and cartilage: inductive signals, stem cells, and biomimetic biomaterials. , 2000, Tissue engineering.

[19]  D. Kallmes,et al.  Bone morphogenetic proteins and bone morphogenetic protein gene therapy in neurological surgery: a review. , 2000, Neurosurgery.

[20]  R. Jilka,et al.  Essential Requirement of BMPs‐2/4 for Both Osteoblast and Osteoclast Formation in Murine Bone Marrow Cultures from Adult Mice: Antagonism by Noggin , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  K. Johnson,et al.  Evaluation of recombinant human bone morphogenetic protein‐2 as a bone‐graft substitute in a canine segmental defect model , 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[22]  D. Schlenzka,et al.  Experimental anterior spine fusion using bovine bone morphogenetic protein: a study in rabbits , 2000, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.

[23]  S. Ludwig,et al.  Osteoinductive bone graft substitutes , 2000, European Spine Journal.

[24]  M. Urist,et al.  Bone Morphogenetic Protein Excipients: Comparative Observations on Poloxamer , 2000, Plastic and reconstructive surgery.

[25]  T A Einhorn,et al.  Growth Factor Regulation of Fracture Repair , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  H. Uludaǧ,et al.  Carrier systems for bone morphogenetic proteins. , 1999, Clinical orthopaedics and related research.

[27]  A. Mikos,et al.  Synthetic biodegradable polymers for orthopaedic applications. , 1999, Clinical orthopaedics and related research.

[28]  S. Boden Bioactive factors for bone tissue engineering. , 1999, Clinical orthopaedics and related research.

[29]  I. Ishikawa,et al.  Bone regeneration by recombinant human bone morphogenetic protein-2 in rat mandibular defects. An experimental model of defect filling. , 1999, Journal of periodontology.

[30]  Jeffrey Bonadio,et al.  Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration , 1999, Nature Medicine.

[31]  J. Poser,et al.  Novel formulation of fibroblast growth factor‐2 in a hyaluronan gel accelerates fracture healing in nonhuman primates , 1999, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[32]  A Daluiski,et al.  The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. , 1999, The Journal of bone and joint surgery. American volume.

[33]  S. Boden,et al.  Posterolateral Lumbar Intertransverse Process Spine Arthrodesis With Recombinant Human Bone Morphogenetic Protein 2/Hydroxyapatite‐Tricalcium Phosphate After Laminectomy in the Nonhuman Primate , 1999, Spine.

[34]  M. Marone,et al.  Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. , 1999, Journal of spinal disorders.

[35]  P. Robbins,et al.  Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. , 1999, Bone.

[36]  J. Fischgrund,et al.  The Use of Recombinant Human Bone Morphogenetic Protein 2 (rhBMP‐2) to Promote Spinal Fusion in a Nonhuman Primate Anterior Interbody Fusion Model , 1999, Spine.

[37]  B. Cunningham,et al.  Osteogenic protein versus autologous interbody arthrodesis in the sheep thoracic spine. A comparative endoscopic study using the Bagby and Kuslich interbody fusion device. , 1999, Spine.

[38]  K E Healy,et al.  Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. , 1998, Journal of biomedical materials research.

[39]  C. Rey,et al.  Resorbable calcium phosphate bone substitute. , 1998, Journal of biomedical materials research.

[40]  J. Poser,et al.  Potential Role of Fibroblast Growth Factor in Enhancement of Fracture Healing , 1998, Clinical orthopaedics and related research.

[41]  V. Goldberg,et al.  The Effect of Implants Loaded with Autologous Mesenchymal Stem Cells on the Healing of Canine Segmental Bone Defects* , 1998, The Journal of bone and joint surgery. American volume.

[42]  T. Sakou Bone morphogenetic proteins: from basic studies to clinical approaches. , 1998, Bone.

[43]  A. McMahon,et al.  Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. , 1998, Science.

[44]  Hollinger,et al.  Sustained release emphasizing recombinant human bone morphogenetic protein-2. , 1998, Advanced drug delivery reviews.

[45]  G. Finerman,et al.  Regional gene therapy with a BMP‐2‐producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents , 1998, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[46]  F. Kaplan,et al.  Encrypted morphogens of skeletogenesis: biological errors and pharmacologic potentials. , 1998, Biochemical pharmacology.

[47]  J. Wozney,et al.  Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion model. , 1997, Journal of spinal disorders.

[48]  J O Hollinger,et al.  Role of bone substitutes. , 1996, Clinical orthopaedics and related research.

[49]  K. Lyons,et al.  Bone morphogenetic protein-2: biology and applications. , 1996, Clinical orthopaedics and related research.

[50]  G. Mundy Regulation of bone formation by bone morphogenetic proteins and other growth factors. , 1996, Clinical orthopaedics and related research.

[51]  T A Einhorn,et al.  Enhancement of fracture-healing. , 1995, The Journal of bone and joint surgery. American volume.

[52]  S D Cook,et al.  Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. , 1995, The Journal of bone and joint surgery. American volume.

[53]  J. Hollinger,et al.  Osseous regeneration in the rat calvarium using novel delivery systems for recombinant human bone morphogenetic protein-2 (rhBMP-2). , 1994, Journal of biomedical materials research.

[54]  W C Hayes,et al.  Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix. , 1994, Journal of biomedical materials research.

[55]  S. Cook,et al.  Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. , 1994, Clinical orthopaedics and related research.

[56]  K. Takaoka,et al.  Polylactic acid-polyethylene glycol block copolymer. A new biodegradable synthetic carrier for bone morphogenetic protein. , 1993, Clinical orthopaedics and related research.

[57]  E. Wang,et al.  Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. , 1993, Clinical orthopaedics and related research.

[58]  J. Heckman,et al.  The use of bone morphogenetic protein in the treatment of non-union in a canine model. , 1991, The Journal of bone and joint surgery. American volume.

[59]  V. Rosen,et al.  Recombinant human bone morphogenetic protein induces bone formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[60]  V. Goldberg,et al.  Ectopic induction of cartilage and bone by water-soluble proteins from bovine bone using a polyanhydride delivery vehicle. , 1989, Journal of biomedical materials research.

[61]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.

[62]  K Ono,et al.  Ectopic bone induction on and in porous hydroxyapatite combined with collagen and bone morphogenetic protein. , 1988, Clinical orthopaedics and related research.

[63]  A. Reddi,et al.  Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[64]  M. Urist,et al.  Bone: Formation by Autoinduction , 1965, Science.

[65]  J. Huard,et al.  Human skeletal muscle cells in ex vivo gene therapy to deliver bone morphogenetic protein-2. , 2002, The Journal of bone and joint surgery. British volume.

[66]  A SINGLE INJECTION OF RHBMP-2/CALCIUM PHOSPHATE PASTE ACCELERATES HEALING IN A NONHUMAN PRIMATE OSTEOTOMY MODEL , 2001 .

[67]  B. Eppley Reconstruction of Bone Using Calcium Phosphate Bone Cements: A Critical Review , 2001 .

[68]  M. F. Macnicol Patterns of musculoskeletal infection in childhood. , 2001, The Journal of bone and joint surgery. British volume.

[69]  0850 - ACCELERATED FRACTURE HEALING BY PERCUTANEOUS INJECTION OF rhBMP-2 AND alpha-BSM , 2000 .

[70]  A SINGLE INJECTION OF rhBMP-2 ENHANCES FRACTURE HEALING IN A RABBIT ULNAR OSTEOTOMY MODEL , 2000 .

[71]  R. Zernicke,et al.  Bone Affinity of a Bisphosphonate‐Conjugated Protein in Vivo , 2000, Biotechnology progress.

[72]  Bone Morphogenetic Protein Biodegradable Bone Remodeling Bone Cement AN INJECTABLE ENDOTHERMICALLY-SETTING CALCIUM PHOSPHATE MATERIAL BRIDGES CRITICAL-SIZED DEFECTS IN RABBITS IN COMBINATION WITH RHBMP-2 , 1999 .

[73]  M. Hadley,et al.  The safety of OP-1 for lumbar fusion with decompression-- a canine study. , 1999, Neurosurgery.

[74]  R. Coutts,et al.  Growth factors as therapeutic agents. , 1997, Instructional course lectures.

[75]  D. Kohn,et al.  Development and characterization of a biodegradable polyphosphate. , 1997, Journal of biomedical materials research.

[76]  T. Einhorn,et al.  Growth factor treatment of fractures. , 1997, Instructional course lectures.

[77]  J H Brekke,et al.  A rationale for delivery of osteoinductive proteins. , 1996, Tissue engineering.

[78]  M. Urist,et al.  Composites of bone morphogenetic protein (BMP) and type IV collagen, coral-derived coral hydroxyapatite, and tricalcium phosphate ceramics , 1996, International Orthopaedics.

[79]  K. Leong,et al.  Poly(α-hydroxy acids). Carriers for bone morphogenetic proteins , 1996 .